JO2454B1 - Selective peptide rings - Google Patents

Selective peptide rings

Info

Publication number
JO2454B1
JO2454B1 JO2001138A JOP20010138A JO2454B1 JO 2454 B1 JO2454 B1 JO 2454B1 JO 2001138 A JO2001138 A JO 2001138A JO P20010138 A JOP20010138 A JO P20010138A JO 2454 B1 JO2454 B1 JO 2454B1
Authority
JO
Jordan
Prior art keywords
cyclic peptides
selective cyclic
selective
peptides
melanocortin
Prior art date
Application number
JO2001138A
Other languages
Arabic (ar)
English (en)
Inventor
واي هينج تشيونج أدريان
سويستوك جوزيف
الان ياغالوف كيث
تشين لي
دنهو وليد
شو اكسن-جي
وانج ياو
Original Assignee
اف . هوفمان لاروش ايه جي
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by اف . هوفمان لاروش ايه جي filed Critical اف . هوفمان لاروش ايه جي
Application granted granted Critical
Publication of JO2454B1 publication Critical patent/JO2454B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JO2001138A 2000-08-30 2001-08-23 Selective peptide rings JO2454B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22918400P 2000-08-30 2000-08-30

Publications (1)

Publication Number Publication Date
JO2454B1 true JO2454B1 (en) 2008-10-09

Family

ID=22860145

Family Applications (1)

Application Number Title Priority Date Filing Date
JO2001138A JO2454B1 (en) 2000-08-30 2001-08-23 Selective peptide rings

Country Status (35)

Country Link
US (1) US7045591B2 (https=)
EP (1) EP1315750B1 (https=)
JP (1) JP4217069B2 (https=)
KR (1) KR100483300B1 (https=)
CN (1) CN100491396C (https=)
AR (2) AR030504A1 (https=)
AT (1) ATE353918T1 (https=)
AU (2) AU2001284026B2 (https=)
BR (1) BR0113637A (https=)
CA (1) CA2420058C (https=)
CY (1) CY1106562T1 (https=)
CZ (1) CZ2003584A3 (https=)
DE (1) DE60126624T2 (https=)
DK (1) DK1315750T3 (https=)
EC (1) ECSP034503A (https=)
ES (1) ES2280393T3 (https=)
HR (1) HRP20030126B1 (https=)
HU (1) HUP0303078A3 (https=)
IL (2) IL154575A0 (https=)
JO (1) JO2454B1 (https=)
MA (1) MA27681A1 (https=)
MX (1) MXPA03001721A (https=)
MY (1) MY137457A (https=)
NO (1) NO20030916L (https=)
NZ (1) NZ523989A (https=)
PA (1) PA8527201A1 (https=)
PE (1) PE20020483A1 (https=)
PL (1) PL366630A1 (https=)
PT (1) PT1315750E (https=)
RU (1) RU2239642C1 (https=)
SI (1) SI1315750T1 (https=)
TW (1) TWI248941B (https=)
WO (1) WO2002018437A2 (https=)
YU (1) YU15603A (https=)
ZA (1) ZA200301015B (https=)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1409521A2 (en) * 2001-07-12 2004-04-21 Merck & Co., Inc. Cyclic peptides as potent and selective melanocortin-4 receptor agonists
CA2462200A1 (en) 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US7456184B2 (en) 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7732451B2 (en) 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7655658B2 (en) 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
US7354923B2 (en) 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
WO2004005324A2 (en) 2002-07-09 2004-01-15 Palatin Technologies, Inc. Peptide composition for treatment of sexual dysfunction
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
KR20060026011A (ko) 2003-05-09 2006-03-22 노보 노르디스크 에이/에스 비만 치료용 펩티드
BRPI0409976A (pt) * 2003-05-09 2006-05-09 Novo Nordisk As composto, métodos para retardar a progressão de igt diabetes do tipo 2, para retardar a progressão de diabetes do tipo 2 para diabetes que requer insulina, para tratar obesidade ou prevenir excesso de peso para regular o apetite para induzir saciedade, para prevenir ganho de peso após se ter tido sucesso em perder peso, para aumentar dispêndio de energia, para tratar uma doença ou estado e para tratar bulimia, composição farmacêutica, e, uso de um composto
CA2530024A1 (en) * 2003-06-19 2005-01-06 Eli Lilly And Company Melanocortin receptor 4(mc4) agonists and their uses
WO2005000338A1 (en) * 2003-06-19 2005-01-06 Eli Lilly And Company Uses of melanocortin-3 receptor (mc3r) agonist peptides
US7084111B2 (en) 2003-06-23 2006-08-01 University Of Florida Research Foundation, Inc. Melanocortin receptor templates, peptides, and use thereof
EP1670815A2 (en) * 2003-09-30 2006-06-21 Novo Nordisk A/S Melanocortin receptor agonists
US7550602B1 (en) 2004-01-14 2009-06-23 Palatin Technologies, Inc. Small molecule compositions for sexual dysfunction
US6974187B2 (en) * 2004-01-28 2005-12-13 Tachi-S Co., Ltd. Vehicle seat structure
US20070123453A1 (en) * 2004-03-29 2007-05-31 Heiman Mark L Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continuous infusion
KR101176758B1 (ko) * 2004-04-08 2012-08-23 아스테라스 세이야쿠 가부시키가이샤 화합물 ｗｓ727713
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
EP1809665A2 (en) * 2004-11-04 2007-07-25 Novo Nordisk A/S Mc4r selective peptides and their use in the treatment of obesity
JP2008519008A (ja) * 2004-11-04 2008-06-05 ノボ ノルディスク アクティーゼルスカブ 肥満症の治療に使用するためのペプチド
EP1809666A2 (en) * 2004-11-04 2007-07-25 Novo Nordisk A/S Peptides for use in the treating obesity
JP2008519009A (ja) * 2004-11-04 2008-06-05 ノボ ノルディスク アクティーゼルスカブ 肥満症の治療に使用するためのペプチド
CN101203527A (zh) * 2005-05-31 2008-06-18 耶路撒冷希伯来大学伊森姆研究发展公司 主链环化的促黑皮质素激素（αMSH）类似物
US20090042790A1 (en) * 2005-06-13 2009-02-12 Nastech Pharmaceutical Company Inc. Transmucosal delivery of peptide derivatives
US20080015304A1 (en) 2006-07-13 2008-01-17 Klaus Hintzer Aqueous emulsion polymerization process for producing fluoropolymers
US7671112B2 (en) * 2005-07-15 2010-03-02 3M Innovative Properties Company Method of making fluoropolymer dispersion
GB2430437A (en) * 2005-09-27 2007-03-28 3M Innovative Properties Co Method of making a fluoropolymer
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
EP2125862A1 (en) * 2006-12-29 2009-12-02 F. Hoffmann-Roche AG Methods for the synthesis of cyclic peptides
CN101605728B (zh) * 2007-02-16 2013-07-24 3M创新有限公司 用于从水中去除含氟化合物的系统和方法
US20080264864A1 (en) * 2007-04-27 2008-10-30 3M Innovative Properties Company PROCESS FOR REMOVING FLUORINATED EMULSIFIER FROM FLUOROPOLMER DISPERSIONS USING AN ANION-EXCHANGE RESIN AND A pH-DEPENDENT SURFACTANT AND FLUOROPOLYMER DISPERSIONS CONTAINING A pH-DEPENDENT SURFACTANT
ES2618315T3 (es) 2007-05-25 2017-06-21 Ipsen Pharma S.A.S. Ligandos del receptor de melanocortina modificados con hidantoína
US8258313B2 (en) 2007-07-19 2012-09-04 Tokuyama Corporation Compound having hydantoin ring and method of producing the same
ES2464102T3 (es) 2008-03-27 2014-05-30 Grünenthal GmbH Derivados de 4-aminociclohexano sustituidos
EP2280941B1 (de) * 2008-03-27 2015-05-06 Grünenthal GmbH (hetero-)aryl-cyclohexan-derivate
KR101687037B1 (ko) 2008-06-09 2016-12-15 팔라틴 테크놀로지스 인코포레이티드 성기능 장애 치료용 멜라노코르틴 수용체-특이적 펩티드
TW201002340A (en) * 2008-06-09 2010-01-16 Palatin Technologies Inc Melanocortin receptor-specific peptides for treatment of obesity
KR101726893B1 (ko) 2009-06-08 2017-04-13 팔라틴 테크놀로지스 인코포레이티드 멜라노코르틴 수용체-특이적 펩티드
WO2010144341A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
WO2011063366A1 (en) 2009-11-23 2011-05-26 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
JP2013511554A (ja) 2009-11-23 2013-04-04 パラティン テクノロジーズ，インコーポレイテッド メラノコルチン−１受容体特異的線状ペプチド
RU2020120797A (ru) 2013-03-15 2020-07-02 Ритм Фармасьютикалз, Инк. Пептидные композиции
GB201416351D0 (en) * 2014-09-16 2014-10-29 Shire Internat Gmbh Heterocyclic derivatives
GB201416352D0 (en) 2014-09-16 2014-10-29 Shire Internat Gmbh Spirocyclic derivatives
US20180022780A1 (en) * 2014-09-26 2018-01-25 Bayer Pharma Aktiengesellschaft Stabilization adrenomedullin derivatives and use thereof
US11542302B2 (en) 2015-10-15 2023-01-03 Arizona Board Of Regents On Behalf Of The University Of Arizona Modulators of melanocortin receptors for the treatment of depression and anxiety
WO2017066754A1 (en) 2015-10-15 2017-04-20 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for the treatment of depression and anxiety
US10899793B2 (en) 2016-05-27 2021-01-26 Regents Of The University Of Minnesota Melanocortin ligands and methods of use thereof
US20190255142A1 (en) * 2016-10-17 2019-08-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Novel modulators of melanocortin receptors for the treatment of depression and anxiety
US11124541B2 (en) 2016-10-18 2021-09-21 Regents Of The University Of Minnesota Chimeric melanocortin ligands and methods of use thereof
CN106496008A (zh) * 2016-10-20 2017-03-15 上海毕得医药科技有限公司 一种合成4‑(4‑氯苯基)环己酮的方法
CN106496005B (zh) * 2016-10-20 2019-04-09 上海毕得医药科技有限公司 一种4-(4-氯苯基)环己酮的合成方法
US10745444B2 (en) * 2017-04-17 2020-08-18 National Tsing Hua University Cyclopeptide, pharmaceutical or cosmetic composition comprising the same and method for preparing the same
US11332499B2 (en) 2018-08-16 2022-05-17 Regents Of The University Of Minnesota Cyclic peptides and methods of use thereof
CN118530294B (zh) * 2024-05-10 2025-02-14 浙江大学 一种芳基二胺固载连接子、其前体以及制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4237456A1 (de) * 1992-11-06 1994-05-11 Merck Patent Gmbh Cyclopeptide
US5811391A (en) 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
US5731408A (en) * 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
US5858972A (en) 1996-01-11 1999-01-12 La Jolla Cancer Research Foundation Antithrombotic agents and methods of use
SE9700620D0 (sv) * 1997-02-21 1997-02-21 Wapharm Ab Cykliska peptider med selektivitet för MSH-receptor subtyper
DK1165613T3 (da) 1999-03-29 2008-08-25 Procter & Gamble Melanocortinreceptorligander

Also Published As

Publication number Publication date
CN1451017A (zh) 2003-10-22
AR030504A1 (es) 2003-08-20
DE60126624D1 (de) 2007-03-29
PT1315750E (pt) 2007-05-31
IL154575A0 (en) 2003-09-17
WO2002018437A3 (en) 2002-06-06
MA27681A1 (fr) 2006-01-02
SI1315750T1 (sl) 2007-06-30
CY1106562T1 (el) 2012-01-25
TWI248941B (en) 2006-02-11
AR061422A2 (es) 2008-08-27
DK1315750T3 (da) 2007-06-11
JP4217069B2 (ja) 2009-01-28
US7045591B2 (en) 2006-05-16
ECSP034503A (es) 2003-04-25
NO20030916D0 (no) 2003-02-27
YU15603A (sh) 2006-05-25
AU2001284026B2 (en) 2007-03-01
BR0113637A (pt) 2004-02-25
HRP20030126A2 (en) 2005-10-31
ZA200301015B (en) 2004-05-05
JP2004507558A (ja) 2004-03-11
ATE353918T1 (de) 2007-03-15
WO2002018437A2 (en) 2002-03-07
CZ2003584A3 (cs) 2003-08-13
KR100483300B1 (ko) 2005-04-15
CN100491396C (zh) 2009-05-27
HUP0303078A2 (hu) 2003-12-29
PA8527201A1 (es) 2002-04-25
KR20030061788A (ko) 2003-07-22
PE20020483A1 (es) 2002-06-06
AU8402601A (en) 2002-03-13
RU2239642C1 (ru) 2004-11-10
ES2280393T3 (es) 2007-09-16
CA2420058A1 (en) 2002-03-07
NO20030916L (no) 2003-02-27
CA2420058C (en) 2009-04-07
NZ523989A (en) 2004-08-27
HRP20030126B1 (en) 2009-01-31
EP1315750A2 (en) 2003-06-04
MY137457A (en) 2009-01-30
US20020143141A1 (en) 2002-10-03
EP1315750B1 (en) 2007-02-14
MXPA03001721A (es) 2003-05-27
DE60126624T2 (de) 2007-11-22
HUP0303078A3 (en) 2012-02-28
IL154575A (en) 2008-12-29
PL366630A1 (en) 2005-02-07

Similar Documents

Publication Publication Date Title
JO2454B1 (en) Selective peptide rings
AUPO755097A0 (en) Receptor agonist and antagonist
NO983431D0 (no) Anti-kl°emidler
EA200300441A1 (ru) Ассоциация антагониста рецептора св1 и сибутрамина, содержащие их фармацевтические композиции и их применение для лечения ожирения
GB0115862D0 (en) Compounds
BR0015963A (pt) Compostos de uréia antagonistas receptor muscarìnico, composições farmacêuticas compreendendo tais compostos e método de preparação destes compostos
ATE398630T1 (de) Zyklische conotoxin-peptide
DE69532162D1 (de) Cannabinoid-rezeptor-antagonisten
DE69929235D1 (de) Spiro-indole als y5-rezeptor antagonisten
YU19903A (sh) Novi receptor nukleinskih kiselina i polipeptida
EA200100519A1 (ru) Композиции на основе тонкоизмельченного эплеренона
AU2001229491A1 (en) Cyclic peptides as potent and selective melanocortin-4 receptor antagonists
WO2003006604A3 (en) Cyclic peptides as potent and selective melanocortin-4 receptor agonists
BR9809071A (pt) Agentes farmacológicos
HUP0402496A2 (hu) Módosított polipeptidek
PE20010516A1 (es) Peptidos ciclicos con afinidad mejorada por los receptores de somatostatina
ATE288268T1 (de) Nichtpeptidische antagonisten des glp-1 rezeptors und verwendungsmethoden
ATE247130T1 (de) Inhibitoren für den urokinaserezeptor
DE60015187D1 (de) Urotensin-ii rezeptorantagonisten
ATE405577T1 (de) Lactam dipeptid und dessen verwendung zur inhibierung der beta-amyloid peptid frisetzung
UY26913A1 (es) Péptidos cíclicos selectivos
MXPA04004757A (es) Uso de una ascomicina para el tratamiento de blefaritis.
WO2004067093A3 (en) Nk1 receptor antagonists for the treatment of functional dyspepsia
DE60220305D1 (de) Verbrückte bicyclische (1,4) benzodiazepine als vasopressinrezeptorantagonisten
PL1668027T3 (pl) Cykliczne peptydy działające jako antagoniści Urotensyny-II